4-Methylpiperidine-4-thiol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Methylpiperidine-4-thiol
• 英文别名: 4-methylpiperidine-4-thiol
• 化学式: C₆H₁₃NS
• 分子量: 131.24
• InChiKey: QFBUBFLXYRGTMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  13
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：EP3831827A1

  公开（公告）日：2021-06-09

  A compound represented by formula I or a pharmaceutically acceptable salt thereof and a use thereof in preparing a drug for treating, stopping or preventing a disease or disorder mediated by FGFR4 activity.

  一种由式 I 代表的化合物或其药学上可接受的盐及其在制备治疗、阻止或预防由 FGFR4 活性介导的疾病或紊乱的药物中的用途。
• Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

  公开号：US10647687B2

  公开（公告）日：2020-05-12

  The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及作为非凋亡调节细胞死亡抑制剂的螺吡嗪化合物，以及含有此类化合物的药物组合物。此外，本发明还涉及此类化合物和药物组合物在治疗中的用途，特别是在治疗以非凋亡调节性细胞死亡为特征或非凋亡调节性细胞死亡可能起作用或起重要作用的病症、紊乱或疾病中的用途。本文所述的化合物和药物组合物还可用于治疗以氧化应激为特征的病症、紊乱或疾病，或氧化应激可能起作用或起重要作用的病症、紊乱或疾病；和/或(1)坏死体的一种或多种成分；(2)死亡结构域受体；和/或(3)Toll 样受体；和/或(4)铁变态反应/铁变态反应信号的参与者，或(1)至(3)和/或(4)中任何一种的激活可能起或起重要作用的情况、紊乱或疾病。
• ADO-resistant cysteamine analogs and uses thereof
  申请人：HORIZON ORPHAN LLC

  公开号：US10906904B2

  公开（公告）日：2021-02-02

  The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

  本公开涉及治疗半胱胺可用于治疗的疾病的方法以及在这些方法中有用的化合物。
• ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF
  申请人：Horizon Orphan LLC

  公开号：EP3316877B1

  公开（公告）日：2019-10-30
• Use of Thiol Compounds to Treat Neurological Disease
  申请人：MERCAPTOR DISCOVERIES, INC.

  公开号：US20190029977A1

  公开（公告）日：2019-01-31

  The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.